Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma

被引:12
作者
Laukhtina, Ekaterina [1 ,2 ]
Pradere, Benjamin [1 ,3 ]
D'Andrea, David [1 ]
Rosiello, Giuseppe [4 ,5 ,6 ]
Luzzago, Stefano [4 ,7 ]
Pecoraro, Angela [4 ,8 ]
Palumbo, Carlotta [4 ,9 ,10 ]
Knipper, Sophie [4 ,11 ]
Karakiewicz, Pierre, I [4 ]
Margulis, Vitaly [12 ]
Quhal, Fahad [1 ,13 ]
Sari Motlagh, Reza [1 ]
Mostafaei, Hadi [1 ,14 ]
Mori, Keiichiro [1 ,15 ]
Schuettfort, Victor M. [1 ,16 ]
Enikeev, Dmitry [2 ]
Shariat, Shahrokh F. [1 ,2 ,12 ,17 ,18 ,19 ,20 ,21 ]
机构
[1] Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, Vienna, Austria
[2] Sechenov Univ, Inst Urol & Reprod Hlth, Moscow, Russia
[3] Univ Hosp Tours, Dept Urol, Tours, France
[4] Univ Montreal Hlth Ctr, Div Urol, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada
[5] IRCCS San Raffaele Sci Inst, Dept Urol, Milan, Italy
[6] IRCCS San Raffaele Sci Inst, Div Expt Oncol, Urol Res Inst URI, Milan, Italy
[7] IRCCS, Dept Urol, European Inst Oncol, Milan, Italy
[8] Univ Turin, San Luigi Gonzaga Hosp, Dept Urol, Turin, Italy
[9] ASST Spedali Civili Brescia, Dept Med & Surg Specialties, Urol Unit, Brescia, Italy
[10] Univ Brescia, Radiol Sci & Publ Hlth, Brescia, Italy
[11] Univ Hosp Hamburg Eppendorf, Martini Klin Prostate Canc Ctr, Hamburg, Germany
[12] Univ Texas Southwestern Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA
[13] King Fahad Specialist Hosp, Dept Urol, Dammam, Saudi Arabia
[14] Tabriz Univ Med Sci, Res Ctr Evidence Based Med, Tabriz, Iran
[15] Jikei Univ, Dept Urol, Sch Med, Tokyo, Japan
[16] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany
[17] Weill Cornell Med Coll, Dept Urol, New York, NY USA
[18] Charles Univ Prague, Fac Med 2, Dept Urol, Prague, Czech Republic
[19] Karl Landsteiner Inst Urol & Androl, Vienna, Austria
[20] Univ Jordan, Jordan Univ Hosp, Dept Special Surg, Div Urol, Amman, Jordan
[21] European Assoc Urol Res Fdn, Arnhem, Netherlands
来源
MINERVA UROLOGY AND NEPHROLOGY | 2022年 / 74卷 / 03期
关键词
Renal cell carcinoma; Neoplasm metastasis; Cytoreduction surgical procedures; Nephrectomy; Survival; Mortality; LYMPHOCYTE RATIO; SURVIVAL; MODEL;
D O I
10.23736/S2724-6051.21.04023-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Identifying those of patients with metastatic renal cell carcinoma (mRCC) who are most likely to benefit from cytoreductive nephrectomy (CN) is challenging. We tested the association between preoperative value of Systemic Immune-Inflammation Index (SII) and overall survival (OS) as well as cancer-specific survival (CSS) in mRCC patients treated with CN. METHODS: mRCC patients treated with CN at different institutions were included. After assessing for the optimal pretreatment SII cut-off value, we found 710 to have the maximum Youden Index value. The overall population was therefore divided into two SII groups using this cut-off (low, <710 vs. high, >= 710). Univariable and multivariable Cox regression analyses tested the association SII and OS as well as CSS. The discrimination of the model was evaluated with the Harrel's Concordance Index (C-Index). The clinical value of the SII was evaluated with decision curve analysis (DCA). RESULTS: Among 613 mRCC patients, 298 (49%) patients had a SII>710. Median follow-up was 31 (IQR 16-58) months. On univariable analysis, high preoperative serum SII was significantly associated with worse OS (HR: 1.28, 95% CI: 1.07-1.54, P=0.01) and CSS (HR: 1.29, 95% CI: 1.08-1.55, P=0.01). On multivariable analysis, which adjusted for the effect of established clinicopathologic features, SII >= 710 was associated with OS (HR: 1.25, 95% CI: 1.04-1.50, P=0.02) and CSS (HR: 1.26, 95% CI: 1.05-1.52, P=0.01). The addition of SII only slightly improved the discrimination of a base model that included established clinicopathologic features (C-index: 0.637 vs. 0.629). On DCA, the inclusion of SII did not improve the net-benefit of the prognostic model. On multivariable analyses, SII >= 710 remained independently associated with the worse OS and CSS in IMDC intermediate risk group (both: HR: 1.31, 95% CI: 1.02-1.67, P=0.03). In the subgroup analyses based on the BMI, among patients with BMI 25, SII was significantly associated with OS (HR: 1.29., 95% CI: 1.04-1.61, P=0.02) and CSS (HR: 1.31, 95% CI: 1.05-1.63, P=0.02). CONCLUSIONS. We found an independent association of high SII prior to CN with unfavorable clinical outcomes, particularly in patients with intermediate risk mRCC and patients with increased BMI. Despite these results, it does not seem to add any prognostic or clinical benefit beyond that obtained by currently available clinicopathologic characteristics as sole worker.
引用
收藏
页码:329 / 336
页数:8
相关论文
共 24 条
[1]   Predictors of Progression-Free Survival and Overall Survival in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Single-Center Experience [J].
Barua, Sasanka Kumar ;
Singh, Yashasvi ;
Baruah, Saumar Jyoti ;
Rajeev, T. P. ;
Bagchi, Puskal K. ;
Sarma, Debanga ;
Phukan, Mandeep .
WORLD JOURNAL OF ONCOLOGY, 2019, 10 (02) :101-111
[2]   The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: A review [J].
Boissier, Romain ;
Campagna, Jennifer ;
Branger, Nicolas ;
Karsenty, Gilles ;
Lechevallier, Eric .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (04) :135-141
[3]   External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model [J].
Chrom, Pawel ;
Zolnierek, Jakub ;
Bodnar, Lubomir ;
Stec, Rafal ;
Szczylik, Cezary .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (05) :526-532
[4]   Inflammation and cancer [J].
Coussens, LM ;
Werb, Z .
NATURE, 2002, 420 (6917) :860-867
[5]   Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer [J].
D'Andrea, David ;
Soria, Francesco ;
Zehetmayer, Sonja ;
Gust, Kilian M. ;
Korn, Stephan ;
Witjes, J. Alfred ;
Shariat, Shahrokh F. .
BJU INTERNATIONAL, 2019, 123 (06) :959-967
[6]   Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab [J].
De Giorgi, Ugo ;
Procopio, Giuseppe ;
Giannarelli, Diana ;
Sabbatini, Roberto ;
Bearz, Alessandra ;
Buti, Sebastiano ;
Basso, Umberto ;
Mitterer, Manfred ;
Ortega, Cinzia ;
Bidoli, Paolo ;
Ferrau, Francesco ;
Crino, Lucio ;
Frassoldati, Antonio ;
Marchetti, Paolo ;
Mini, Enrico ;
Scoppola, Alessandro ;
Verusio, Claudio ;
Fornarini, Giuseppe ;
Carteni, Giacomo ;
Caserta, Claudia ;
Sternberg, Cora N. .
CLINICAL CANCER RESEARCH, 2019, 25 (13) :3839-3846
[7]  
Fukuda Hironori, 2018, Oncotarget, V9, P14296, DOI 10.18632/oncotarget.24507
[8]   Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer [J].
Gunduz, Seyda ;
Mutlu, Hasan ;
Tural, Deniz ;
Yildiz, Ozcan ;
Uysal, Mukremin ;
Coskun, Hasan Senol ;
Bozcuk, Hakan .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 (04) :288-292
[9]   Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review [J].
Gupta, Kiran ;
Miller, Jeffrey D. ;
Li, Jim Z. ;
Russel, Mason W. ;
Charbonneau, Claudie .
CANCER TREATMENT REVIEWS, 2008, 34 (03) :193-205
[10]   External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study [J].
Heng, Daniel Y. C. ;
Xie, Wanling ;
Regan, Meredith M. ;
Harshman, Lauren C. ;
Bjarnason, Georg A. ;
Vaishampayan, Ulka N. ;
Mackenzie, Mary ;
Wood, Lori ;
Donskov, Frede ;
Tan, Min-Han ;
Rha, Sun-Young ;
Agarwal, Neeraj ;
Kollmannsberger, Christian ;
Rini, Brian I. ;
Choueiri, Toni K. .
LANCET ONCOLOGY, 2013, 14 (02) :141-148